Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan appoints new president of Asia-Pacific
Mr Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, US and
Mr Montgomery has worked for over 30 years in the pharmaceuticals industry and has extensive experience in both patented and generics pharmaceutical products in the UK, US and
Under the alliance agreement, Sanofi Pasteur will have access to antigens identified by Institut Pasteur derived from plasmodium falciparum, the parasite responsible for the most deadly malaria infections.
The trial was a randomized, double-blind, three-arm placebo-controlled study, the primary endpoint of which was change from baseline to week six on the positive and negative syndrome scale
The denial is based on results of animal toxicology studies filed by Cortex. As a result, the company has requested that the division of psychiatry products of the
The agency requires additional time to review information regarding the proposed Tysabri (natalizumab) risk management plan for crohn’s disease. Under this revised timeline, the companies anticipate action from
ALO-01 (extended-release morphine sulfate plus sequestered naltrexone) showed similar effectiveness to Alpharma’s extended-release oral formulation of morphine sulfate, Kadian, and maintained pain reduction throughout the study. The sequestered
The agreement has determined that the design and planned analysis of the study addresses the objectives necessary to support a regulatory submission. The trial comparing weekly 100mg/m2 Abraxane
The analysis was based on data pooled from the ASCEND I and II studies, which included 349 patients dosed at 2.4 g/day. Results indicated that the median time
Under the terms of the settlement, Barr will have the right to launch generic versions of diastat and diastat AcuDial on or after September 1, 2010, or earlier
The submission includes, in addition to a required routine safety update and revised product labeling, the results of three non-clinical (in vitro) studies that provide clarifying information about